Lipoprotein lipase gene therapy - Avigen

Drug Profile

Lipoprotein lipase gene therapy - Avigen

Latest Information Update: 07 Sep 2005

Price : $50

At a glance

  • Originator Avigen
  • Class Gene therapies
  • Mechanism of Action Lipoprotein lipase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypertriglyceridaemia

Most Recent Events

  • 27 Jun 2005 Discontinued - Preclinical for Hypertriglyceridaemia in USA (IM)
  • 18 Mar 1998 New profile
  • 18 Mar 1998 Preclinical development for Hypertriglyceridaemia in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top